The Clinical and Administrative Core (Core D) is designed to: 1) Facilitate interactions between Projects and Cores;2) Provide administrative support for: a) GTRP applications and interactions (Clinical Grade Vector manufacture, Biodistribution &Toxicology Studies);and b) manage IND submissions (Project 1, and perhaps Project 2). Organizational and Administrative Structure. The Principal Investigator of the proposed Program, Dr. H. Kirk Hammond, will be responsible for all operations and policy decisions of the program. He will report to and be assisted by several Program Committees including: a) Local Advisory Committee. This Committee will be comprised of the Project Leaders of all the research components (Drs. Hammond, Roth, and Dillmann). The committee will meet quarterly to identify and solve problems related to general programmatic issues and evaluate progress toward the program's goals;b) External Advisory Committee. This Committee consists of three basic and clinical research investigators with expertise directly relevant to gene transfer, cardiovascular physiology and heart failure. The committee will meet in La Jolla annually to confer with the Principal Investigator and the participating investigators in the program. These clinicians and scientists will play an important advisory role in the implementation, oversight, and data assessment in the overall Program;c) Data and Safety Monitoring Board (DSMB). The NHLBI DSMB will assess any clinical trials that are initiated in the tenure of the proposed renewal Program, as mandated by the NIH. The day-to-day operations of the program including program development and oversight will be coordinated through Dr. Hammond. The local site administrative personnel will include an experienced and senior program Administrative Assistant (Ms. Eileen D'Souza).

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Program Projects (P01)
Project #
Application #
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Veterans Medical Research Fdn/San Diego
San Diego
United States
Zip Code
Pfeiffer, E R; Wright, A T; Edwards, A G et al. (2014) Caveolae in ventricular myocytes are required for stretch-dependent conduction slowing. J Mol Cell Cardiol 76:265-74
Wang, Jiawan; Schilling, Jan M; Niesman, Ingrid R et al. (2014) Cardioprotective trafficking of caveolin to mitochondria is Gi-protein dependent. Anesthesiology 121:538-48
Lee, Kristen L; Hoey, David A; Spasic, Milos et al. (2014) Adenylyl cyclase 6 mediates loading-induced bone adaptation in vivo. FASEB J 28:1157-65
Tang, Tong; Lai, N Chin; Wright, Adam T et al. (2013) Adenylyl cyclase 6 deletion increases mortality during sustained *-adrenergic receptor stimulation. J Mol Cell Cardiol 60:60-7
Gao, Mei Hua; Lai, Ngai Chin; Tang, Tong et al. (2013) Preserved cardiac function despite marked impairment of cAMP generation. PLoS One 8:e72151
Tang, Tong; Hammond, H Kirk (2013) Gene transfer for congestive heart failure: update 2013. Transl Res 161:313-20
Rieg, Timo; Tang, Tong; Uchida, Shinichi et al. (2013) Adenylyl cyclase 6 enhances NKCC2 expression and mediates vasopressin-induced phosphorylation of NKCC2 and NCC. Am J Pathol 182:96-106
Gao, Mei Hua; Lai, N Chin; Miyanohara, Atsushi et al. (2013) Intravenous adeno-associated virus serotype 8 encoding urocortin-2 provides sustained augmentation of left ventricular function in mice. Hum Gene Ther 24:777-85
Lai, N Chin; Tang, Tong; Gao, Mei Hua et al. (2012) Improved function of the failing rat heart by regulated expression of insulin-like growth factor I via intramuscular gene transfer. Hum Gene Ther 23:255-61
Tang, T; Gao, M H; Hammond, H Kirk (2012) Prospects for gene transfer for clinical heart failure. Gene Ther 19:606-12

Showing the most recent 10 out of 54 publications